麻豆传媒

SAN DIEGO -- The highly-anticipated -- examining cardiovascular outcomes in certain heart failure patients treated with the MitraClip device -- will be a highlight of the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference, which turns 30 years old this year.

COAPT will be the MitraClip's shot at redemption and features a similar patient population as the MITRA-FR trial, which showed no improvement over medical therapy alone for preventing hard outcomes in heart failure patients with secondary mitral regurgitation. MITRA-FR was recently presented at the European Society of Cardiology meeting.

Other highlights of what investigators are serving up Sept. 21-25 in San Diego include:

• REDUCE-FMR, a sham-controlled trial looking at the Carillon Mitral Contour System for the reduction of mitral regurgitation
• SOLVE-TAVI, a 2x2 trial comparing self-expanding versus balloon-expandable valves and anesthesia versus more mild conscious sedation in transcatheter aortic valve replacement
• Large imaging studies ULTIMATE (intravascular ultrasound to guide drug-eluting stent [DES] placement) and LRP (near-infrared spectroscopy for vulnerable plaque)
• Head-to-head studies on newer-generation DES
• More bioresorbable vascular scaffold data from ABSORB IV and ABSORB COMPARE

"We're expecting tremendous science," said Gregg Stone, MD, of Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation (CRF) in New York City at a media briefing, teasing the 15 late-breaking trials and 12 late-breaking clinical science presentations that will be presented at TCT.

One change to the meeting this year is the addition of a large, hands-on "training destination" where physicians and allied health personnel can learn new skills in pavilions featuring simulators and cadaver hearts. Some of these activities are industry-sponsored, whereas others originated with CRF, Stone noted.

Comment